The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.
Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...
J&J made it into a nasal spray to get it into the brain quickly. Spravato "turns on neural networks in a way that's different," said Mattingly. "Our standard oral antidepressants took weeks to ...
Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...
The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...
Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...
Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a major ...
Stella Mental Health Westmont is a top depression and anxiety clinic near Chicago that offers comprehensive mental health treatments like Spravato (esketamine) therapy, ketamine infusion, stellate ...
Stella Mental Health Westmont is a top depression and anxiety clinic near Chicago that offers comprehensive mental health treatments like Spravato (esketamine) therapy, ketamine infusion, stellate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback